Table 2.
Sociodemographic and cancer characteristics of women 40 and above in the USA by Surgery status (2010–2017)
| Variable | Number of patients (n = 277,127) |
Patients who received surgery (n = 275,641) | Patients with surgery recommended but not performed (n = 1486) | Pearson Chi-square |
|---|---|---|---|---|
| Race and ethnicity | 86.4692*** | |||
| Non-Hispanic White | 191,777 | 190,839 (99.51) | 938 (0.49) | |
| Non-Hispanic Black | 28,250 | 27,993 (99.09) | 257 (0.91) | |
| Hispanic (All races) | 30,813 | 30,673 (99.55) | 140 (0.45) | |
| Other | 26,287 | 26,136 (99.43) | 151 (0.57) | |
| Subtypes | 10.2803* | |||
| Luminal A | 209,996 | 208,897 (99.48) | 1,099 (0.52) | |
| Luminal B | 27,478 | 27,296 (99.34) | 182 (0.66) | |
| HER2 enriched | 10,838 | 10,775 (99.42) | 63 (0.58) | |
| Triple negative | 28,815 | 28,673 (99.51) | 142 (0.49) | |
| Age at diagnosis | 2.3exp(3)*** | |||
| 40–49 | 48,079 | 47,940 (99.71) | 139 (0.29) | |
| 50–59 | 72,810 | 72,571 (99.67) | 239 (0.33) | |
| 60–69 | 81,609 | 81,362 (99.70) | 247 (0.30) | |
| 70–79 | 51,583 | 51,355 (99.56) | 228 (0.44) | |
| 80+ | 23,046 | 22,413 (97.25) | 633 (2.75) | |
| Tumor grade | 26.4617*** | |||
| Grade I; well differentiated | 69,674 | 69,362 (99.55) | 312 (0.45) | |
| Grade II; moderately differentiated | 125,240 | 124,473 (99.39) | 767 (0.61) | |
| Grade III; poorly differentiated | 82,213 | 81,806 (99.50) | 407 (0.50) | |
| Tumor site | 49.6519*** | |||
| Nipple | 1,008 | 1,000 (99.21) | 8 (0.79) | |
| Central portion of the breast | 14,156 | 14,030 (99.11) | 126 (0.89) | |
| Upper-inner quadrant of the breast | 40,050 | 39,842 (99.48) | 208 (0.52) | |
| Lower-inner quadrant of the breast | 17,578 | 17,496 (99.53) | 82 (0.47) | |
| Upper-outer quadrant of the breast | 108,230 | 107,710 (99.52) | 520 (0.48) | |
| Lower-outer quadrant of the breast | 23,767 | 23,656 (99.53) | 111 (0.47) | |
| Axillary tail of the breast | 1,305 | 1,298 (99.46) | 7 (0.54) | |
| Overlapping lesion of the breast | 71,033 | 70,609 (99.40) | 424 (0.60) | |
| Tumor stage | 615.9641*** | |||
| Localized only | 197,500 | 196,538 (99.51) | 962 (0.49) | |
| Regional, direct extension only | 3,423 | 3,311 (96.73) | 112 (3.27) | |
| Regional, lymph nodes only | 68,290 | 67,990 (99.56) | 300 (0.44) | |
| Regional, both direct extension and lymph nodes | 7,914 | 7,802 (98.58) | 112 (1.42) | |
| Marital status | 759.8123*** | |||
| Married | 164,397 | 163,925 (99.71) | 472 (0.29) | |
| Unmarried/Domestic partner | 997 | 996 (99.90) | 1 (0.10) | |
| Divorced | 32,038 | 31,855 (99.43) | 183 (0.57) | |
| Widowed | 37,364 | 36,837 (98.59) | 527 (1.41) | |
| Separated | 3,073 | 3,044 (99.06) | 29 (0.94) | |
| Never married | 39,258 | 38,984 (99.30) | 274 (0.70) | |
| Year of diagnosis | 72.0314*** | |||
| 2010 | 30,717 | 30,611 (99.65) | 106 (0.35) | |
| 2011 | 31,810 | 31,678 (99.59) | 132 (0.41) | |
| 2012 | 33,035 | 32,871 (99.50) | 164 (0.50) | |
| 2013 | 34,302 | 34,142 (99.53) | 160 (0.47) | |
| 2014 | 34,957 | 34,783 (99.50) | 174 (0.50) | |
| 2015 | 36,769 | 36,532 (99.36) | 237 (0.64) | |
| 2016 | 37,470 | 37,219 (99.33) | 251 (0.67) | |
| 2017 | 38,067 | 37,805 (99.31) | 262 (0.69) | |
| Median income | 15.7957** | |||
| < $35,000 | 3,797 | 3,780 (99.55) | 17 (0.45) | |
| $35,000–$44,999 | 19,617 | 19,525 (99.53) | 92 (0.47) | |
| $45,000–$54,999 | 40,359 | 40,130 (99.43) | 229 (0.57) | |
| $55,000–$64,999 | 66,982 | 66,674 (99.54) | 308 (0.46) | |
| $65,000–$74,999 | 58,796 | 58,476 (99.46) | 320 (0.54) | |
| > $75,000 | 87,576 | 87,056 (99.41) | 520 (0.59) | |
| Urban–Rural | 6.8024 ns | |||
| Counties in metropolitan areas greater than 1 million | 172,590 | 171,648 (99.45) | 942 (0.55) | |
| Counties in metropolitan areas of 250 k to 1 million | 58,086 | 57,756 (99.43) | 330 (0.57) | |
| Counties in metropolitan areas less than 250 k | 19,049 | 18,963 (99.55) | 86 (0.45) | |
| Non-metropolitan counties adjacent to a metropolitan area | 15,984 | 15,913 (99.56) | 71 (0.44) | |
| Non-metropolitan counties non-adjacent to a metropolitan area | 11,418 | 11,361 (99.50) | 57 (0.50) | |
| Radiation therapy | 2.2exp(3)*** | |||
| No | 106,188 | 104,747 (98.64) | 1,441 (1.36) | |
| Yes | 161,811 | 161,787 (99.99) | 24 (0.01) | |
| Missing | 9,128 | 9,107 (99.77) | 21 (0.23) | |
| Chemotherapy | 579.0282*** | |||
| No | 171,081 | 169,714 (99.20) | 1,367 (0.80) | |
| Yes | 106,046 | 105,927 (99.89) | 119 (0.11) |
Values are n (% of column total). For the p-value, ns indicates not significant, *p < 0.05, **p < 0.01, ***p < 0.001
HER2 Human epidermal growth factor receptor 2